The federal 340B Drug Pricing Program, which requires pharmaceutical manufacturers participating in Medicaid to sell outpatient drugs at discounted prices to healthcare organizations that care for ...

Abbye E. Alexander, Christopher J. Tellner and Talya Van Embden of Kaufman Dolowich discuss litigation over the 340B Drug Pricing Program, intended to help health care providers serve financially ...

Join AEI’s Kirsten Axelsen and a panel of experts as they discuss reforming the 340B program and addressing both its intended and unintended consequences.

340B could have a new cop on the beat. Hospitals are worried. The Trump administration wants to move oversight of the controversial drug discount program to the CMS, which has a more aggressive ...

He writes that 340B continues to ensure that safety-net health care providers have the resources they need, and it is a successful model that should continue for decades to come.

Top Republican calls for 340B reform in long-awaited investigation The report called on Congress to improve transparency in the program, like requiring covered entities to show how they used 340B ...

For three decades, the 340B drug pricing program has helped hospitals that serve high numbers of low-income patients offer and expand a range of important programs and services that advance health … ...

Reforming 340B can improve the broader health care system while ensuring the program achieves its important mission of improving access for vulnerable populations.

A federal court has rejected a lawsuit by several drugmakers that sought to change the 340B Drug Pricing Program from an upfront payment model to a backend rebate structure.

Eli Lilly contends it should be allowed to vet data from 340B hospitals before providing rebates, rather than offer upfront discounts.